Table 1 Patient characteristics

TKI/PBC

23/4^¤

23/48^¤

46/52

Post-treatment MRI [days]

8.6 ± 4.4^¤

3.9 ± 4.3^¤

5.2 ± 4.8

Mean age

64 ± 9

64 ± 9

64 ± 9

Male

10 (37%)

32 (45%)

42 (43%)

ECOG > 0

15 (56%)

28 (39%)

43 (44%)

Pathologic BMI^♦

4 (15%)

19 (27%)

23 (24%)

Never Smoker

10 (37%)^×

10 (14%)^×

20 (20%)

Pack Years

15 ± 18^¤

33 ± 23^¤

28 ± 23

Vital capacity [l]

2.8 ± 1.1

3.0 ± 1.0

3.0 ± 1.0

Baseline CEA [ng/ml]

294 ± 1259

97 ± 241

149 ± 675

Baseline Cyfra 21.1 [ng/ml]

9.1 ± 11.3

9.1 ± 10.5

9.1 ± 10.7

Baseline NSE [ng/ml]

35 ± 24

27 ± 27

29 ± 27

Tumor

Stage III

0 (0%)

6 (8%)

6 (6%)

Stage IV

27 (100%)

65 (92%)

92 (94%)

T-stage

T1

2 (7%)

7 (10%)

9 (9%)

T2

5 (19%)

18 (25%)

23 (24%)

T3

5 (19%)

18 (25%)

23 (24%)

T4

14 (52%)

28 (39%)

42 (43%)

N-stage

N1 and N2

16 (59%)

42 (59%)

58 (59%)

N3

11 (41%)

29 (41%)

40 (41%)

M-stage

M0

0 (0%)^×

6 (8%)^×

6 (6%)

1 site

4 (15%)

23 (32%)

27 (28%)

2 sites

11 (41%)

21 (30%)

32 (33%)

≥ 3 sites

12 (44%)

21 (30%)

33 (34%)

Metastases

Liver

5 (19%)

16 (23%)

21 (21%)

Brain

9 (33%)

24 (34%)

33 (34%)

Bone

17 (63%)

31 (44%)

48 (49%)

Lung

13 (48%)

22 (31%)

35 (36%)